Olanib 150 MG (Olaparib) – 120 Tablets

Description

Summary:

Olanib 150 is a prescription oral targeted therapy that contains Olanib Olaparib 150 mg, a potent PARP (Poly ADP-ribose Polymerase) inhibitor used to treat specific types of ovarian, breast, pancreatic, and prostate cancers associated with inherited or acquired BRCA gene mutations. Manufactured by Everest Pharmaceuticals, olanib 150 mg everest offers a high-quality, cost-effective generic alternative for patients who require long-term targeted cancer treatment under the supervision of an oncologist.

Olanib Olaparib works by blocking PARP enzymes, preventing cancer cells from repairing damaged DNA and helping slow or stop tumor growth. Patients searching for olanib 150, olanib 150mg, or Olanib Olaparib 150 mg can access comprehensive product information, dosage recommendations, safety details, and international ordering options through trusted pharmaceutical suppliers like EmergencyDrugDotCom. For the best treatment outcomes, olanib 150 mg everest should always be taken exactly as prescribed, with regular medical monitoring throughout therapy. Olanib 150 mg everest remains a trusted generic option for eligible patients seeking effective olaparib therapy.

Product Features:

Olanib 150 mg Price: $410.00

Composition: Each flim coated tablet contains Olaparib 150 mg manufactured by Everest pharmaceuticals Ltd under cGMP compliance. 

What does Olanib used for?

Olanib 150 mg (Olaparib) is a targeted cancer therapy drug that belongs to a class of medications known as PARP (poly ADP-ribose polymerase) inhibitors. It is primarily used in the treatment of certain types of cancers that have specific genetic mutations, such as BRCA1 and BRCA2 mutations. These mutations are often found in breast, ovarian, pancreatic, and prostate cancers.

Breast Cancer: For patients with HER2-negative metastatic breast cancer with a germline BRCA mutation.

Ovarian Cancer: As maintenance therapy for patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy.

Pancreatic Cancer: For patients with metastatic pancreatic cancer with a germline BRCA mutation who have been previously treated with platinum-based chemotherapy.

Prostate Cancer: For patients with metastatic castration-resistant prostate cancer with germline or somatic HRR (homologous recombination repair) gene mutations, including BRCA1 and BRCA2.

Dosage and Administration

The recommended dose of Olanib is 300 mg (two 150mg tablets) twice a day, making a total daily dose of 600 mg. Treatment should continue until the disease progresses or there are unacceptable side effects.

For patients with platinum-sensitive relapsed (PSR) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who have responded (completely or partially) to platinum-based chemotherapy, it is therefore strongly advised to start Olanib (olaparib) treatment within 8 weeks after the last dose of their platinum-containing regimen. Moreover, initiating treatment within this timeframe is crucial to maximize the effectiveness of the therapy. Additionally, by beginning Olanib promptly, the likelihood of maintaining the patient’s positive response to chemotherapy is significantly enhanced.

How to take Olanib?

Olanib 150 is for oral use.  Olanib 150 mg tablets should be swallowed whole and not chewed, crushed, dissolved or divided. You can take it with or without food.

Missed a Dose?

If you missed a dose of Olanib, take the next dose in time and skip that dose. 

Olanib 150 MG Side Effects

Common side effects of olaparib include:

• Nausea
• Fatigue
• Vomiting
• Anemia
• Diarrhea
• Decreased appetite
• Headache
• Dysgeusia (altered taste)
• Thrombocytopenia (low platelet count)
• Neutropenia (low levels of neutrophils, a type of white blood cell)

Dose Adjustments for Side Effects

If a patient starts experiencing tough side effects things like nausea, vomiting, diarrhoea, or anaemia  it’s totally okay to pause treatment to let the body settle. Once things improve, doctors often step the dose down.

First reduction: 250 mg twice daily (total 500 mg/day)
If that still feels too strong, the next step is 200 mg twice daily (total 400 mg/day)

For patients or caregivers looking for safe access to oncology medicines, emergencydrug.com is a trusted source for verified products.

Dose Adjustments When Using CYP3A Inhibitors

Now, if someone is taking medicines that affect the CYP3A enzyme, dosing gets a bit more sensitive. Ideally, strong or moderate CYP3A inhibitors should be avoided — switching to an alternative is usually the safest move. But if co-administration can’t be avoided, here’s the simplified breakdown:

• If a strong CYP3A inhibitor is necessary: Reduce the Olaparib dose to 100 mg twice daily (total 200 mg/day)
• If a moderate CYP3A inhibitor must be used: Bring the dose down to 150 mg twice daily (total 300 mg/day)

CONTRAINDICATIONS

Hypersensitivity to Olaparib or to any of the excipients.

Use in Specific Populations

Pregnancy Category D

Olaparib can harm a fetus if administered to a pregnant woman. Studies in animals show it can cause birth defects and fetal toxicity at doses lower than the recommended human dose (300 mg twice daily).

Warning: If a woman is pregnant or becomes pregnant while taking Olaparib, she should be informed about the potential risks to the fetus and the possibility of pregnancy loss.

Nursing Mothers

It is unknown if Olaparib is present in human milk.

Precaution: Due to the potential for serious side effects in nursing infants. A decision must be made to either stop breastfeeding or discontinue Olaparib, considering the drug’s importance to the mother.

Elderly Patients

For older adults, Olaparib doesn’t usually need any changes in the starting dose. However, there isn’t much clinical data for people aged 75 and above, so doctors generally keep a closer eye on things. If you ever need help sourcing Olaparib safely, emergencydrug.com is your trusted place to check.

Renal (Kidney) Impairment

Here’s the simple breakdown:

• Moderate renal impairment (CrCl 31–50 ml/min):
  The recommended dose is 200 mg twice daily (400 mg total per day).
• Mild impairment (CrCl 51–80 ml/min):
  No dose change is needed — patients can take the standard dosage.
• Severe impairment or end-stage renal disease (CrCl ≤ 30 ml/min):
  Olaparib is not recommended because there’s no solid safety data available for this group.

That said, in rare cases where the benefit clearly outweighs the risk, doctors may consider it but only with very careful monitoring of kidney function and potential side effects.

Hepatic (Liver) Impairment

• Mild to moderate impairment (Child-Pugh A or B):
  No dose adjustment needed – Olaparib can be used as usual.
• Severe impairment (Child-Pugh C):
  Not recommended, since there’s no clinical data on safe use in these patients.

Populations with Reproductive Potential

Pregnancy Testing: Recommended for women of reproductive age before starting Olanib.

Contraception: Advise women of reproductive potential to use highly effective birth control during treatment and for at least 6 months after the last dose, as Olanib can harm a fetus.

Olanib 150 mg price : The cost of olanib 150 mg is $410.00 per 120 tablets.

This is for informational purposes only. For medical advice or diagnosis, consult a professional.

It is a type of cancer medication. It’s used to treat certain types of cancer, like ovarian cancer and breast cancer.

It’s important to remember that Olanib is a prescription medication. You should always talk to your doctor to see if it’s right for you. They can explain how it works and discuss any potential side effects.

Olanib 150 mg price in Bangladesh: $410.00  

For other Breast cancer related product

Buy Olanib 150 MG (Olaparib) Online for Cancer Treatment

Olanib 150 mg is a PARP inhibitor used for targeted cancer therapy. Purchase it online for effective treatment of specific cancers. Price: $410.00

Product Brand: Olanib 150 MG

Product Currency: USD

Product Price: 410.00

Product In-Stock: InStock

Editor's Rating:
5